Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228590 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine APL-130277 in Patients With Parkinson's Disease
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02228590 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 20 participants.
The verdict
NCT02228590, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)
Interventions
- DRUG APL-130277
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-08-31 |
| Est. Completion | 2014-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228590
The ClinicalTrials.gov registry entry for NCT02228590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APL-130277 is the first listed.
NCT02228590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228590 about?
NCT02228590 is a clinical study titled "A Study to Examine APL-130277 in Patients With Parkinson's Disease". The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)
What is the current status of trial NCT02228590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-08-31. Estimated completion is 2014-11-24.
What interventions are being tested in trial NCT02228590?
The interventions under investigation include: APL-130277 (DRUG).
Who is sponsoring clinical trial NCT02228590?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.